These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 23253319)

  • 41. Challenges and opportunities in the management of Clostridium difficile infection.
    DuPont HL
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):863-74. PubMed ID: 25012255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies.
    Parmar SR; Bhatt V; Yang J; Zhang Q; Schuster M
    J Oncol Pharm Pract; 2014 Jun; 20(3):172-82. PubMed ID: 23804627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer.
    Esmaily-Fard A; Tverdek FP; Crowther DM; Ghantoji SS; Adachi JA; Chemaly RF
    Pharmacotherapy; 2014 Nov; 34(11):1220-5. PubMed ID: 25164587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tigecycline for the treatment of severe Clostridium difficile infection.
    Larson KC; Belliveau PP; Spooner LM
    Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update on Clostridium difficile-induced colitis, Part 2.
    Reinke CM; Messick CR
    Am J Hosp Pharm; 1994 Aug; 51(15):1892-901; quiz 1958-9. PubMed ID: 7942924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.
    Sears P; Ichikawa Y; Ruiz N; Gorbach S
    Ann N Y Acad Sci; 2013 Jul; 1291():33-41. PubMed ID: 23672600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Relapsing infections with Clostridium difficile].
    Visser WE; Dingemans-Dumas AM; Bac DJ
    Ned Tijdschr Geneeskd; 2005 Oct; 149(43):2381-5. PubMed ID: 16277125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence].
    Brodszky V; Gulácsi L; Ludwig E; Prinz G; Banai J; Reményi P; Strbák B; Kertész A; Kopcsóné Németh I; Zsoldiné Urbán E; Baji P; Péntek M
    Orv Hetil; 2013 Jun; 154(23):890-9. PubMed ID: 23728312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
    Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
    J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-Analysis.
    Li R; Lu L; Lin Y; Wang M; Liu X
    PLoS One; 2015; 10(10):e0137252. PubMed ID: 26444424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preventing downstream Clostridium difficile infections with upstream antibiotic management.
    Malkan AD; Scholand SJ
    Med Hypotheses; 2012 Jan; 78(1):136-7. PubMed ID: 22079651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosis and treatment of Clostridium difficile in adults: a systematic review.
    Bagdasarian N; Rao K; Malani PN
    JAMA; 2015 Jan; 313(4):398-408. PubMed ID: 25626036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy.
    Jardin CG; Palmer HR; Shah DN; Le F; Beyda ND; Jiang Z; Garey KW
    J Hosp Infect; 2013 Sep; 85(1):28-32. PubMed ID: 23834988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Past, present, and future therapies for Clostridium difficile-associated disease.
    Surowiec D; Kuyumjian AG; Wynd MA; Cicogna CE
    Ann Pharmacother; 2006 Dec; 40(12):2155-63. PubMed ID: 17148650
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis.
    Chung CH; Wu CJ; Lee HC; Yan JJ; Chang CM; Lee NY; Chen PL; Lee CC; Hung YP; Ko WC
    J Microbiol Immunol Infect; 2010 Apr; 43(2):119-25. PubMed ID: 20457428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clostridium-difficile-associated infections].
    Eckert C; Barbut F
    Med Sci (Paris); 2010 Feb; 26(2):153-8. PubMed ID: 20188046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clostridium difficile: a reemerging pathogen.
    Calfee DP
    Geriatrics; 2008 Sep; 63(9):10-21. PubMed ID: 18763846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of infections associated with Clostridium difficile].
    Szczesny A; Martirosian G
    Wiad Lek; 2003; 56(5-6):278-82. PubMed ID: 14526488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Individualized treatment strategies for Clostridium difficile infections].
    Solbach P; Dersch P; Bachmann O
    Internist (Berl); 2017 Jul; 58(7):675-681. PubMed ID: 28589214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.
    Cornely OA; Miller MA; Fantin B; Mullane K; Kean Y; Gorbach S
    J Clin Oncol; 2013 Jul; 31(19):2493-9. PubMed ID: 23715579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.